Themis Medicare Limited · NSE:THEMISMED
Themis Medicare — Q4 FY25 Earnings Presentation
19 slides from Themis Medicare's earnings presentation, May 20, 2025
Slide 1: Investor Presentation Submission Letter to Exchanges
TML/BSE/NSE/2025-26/07 20th May, 2025 The Manager The Manager – Listing Department Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Dalal Street, Mumbai- 400001 Bandra (East), Mumbai- 400051 Scrip C
Slide 2: Themis Medicare Ltd. Result Update Presentation Q4 & FY25
In every possibility lies an innate, latent power to change lives Themis Medicare Ltd. Result Update Presentation Q4 & FY25
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Themis Medicare Limited (the “Company” or “Themis” or “TML”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in
Slide 4: Table of Contents
Table of Contents Consolidated Financial Highlights Company Overview Way Ahead 3
Slide 5: Management Comment
Management Comment Commenting on the result, Dr. Sachin Patel, Managing Director & CEO, said: “In Q4FY25, we faced certain challenges through which we maneuvered successfully. The revenue for this quarter was impacted on account of a major and high-margin institutional business that performed well b
Slide 6: Consolidated Financial Highlights
Consolidated Financial Highlights
Slide 7: Consolidated Quarterly Financial Highlights
Consolidated Quarterly Financial Highlights Revenue (Rs. Cr.)* EBITDA (Rs. Cr.)** / Margin (%) 123.0 117.0 97.8 93.8 23.7% 71.7 14.6% 9.1% 9.5% 29.2 17.1 9.3 8.5 -8.1% Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 -5.8 PAT (Rs. Cr.) / Margin (%) EPS (Rs.) 20.1% 2.68
Slide 8: Consolidated Quarterly Financial Highlights – Q4 FY25
Consolidated Quarterly Financial Highlights – Q4 FY25 Particulars (Rs. Cr.) Q4 FY25 Q4 FY24 Y-o-Y (%) Q3 FY25 Net Revenue 71.70 97.82 (27%) 93.81 Cost of Material Consumed 18.98 21.65 12.76 Purchase of SIT 16.30 11.79 22.51 • Formulation Segment has grown Changes in Inventory (14.68) 5.78 (6.77) by
Slide 9: Consolidated Financial Highlights – FY25
Consolidated Financial Highlights – FY25 Particulars (Rs. Cr.) FY25 FY24 Y-o-Y (%) Net Revenue 405.51 381.76 6.22% Cost of Material Consumed 76.31 84.67 Purchase of SIT 73.67 53.61 Changes in Inventory (17.98) (1.57) Employee Expenses 96.38 82.41 Other Expenses 128.10 111.13 Total Expenditure 356.46
Slide 10: Consolidated Balance Sheet as on 31st Mar'25
Consolidated Balance Sheet as on 31st Mar’25 As on 31st As on 31st As on 31st As on 31st Rs. Cr. Rs. Cr. Mar’25 Mar’24 Mar’25 Mar’24 Shareholders Funds 402.60 377.67 Non Current Assets 284.17 273.25 Share Capital 9.20 9.20 Plant, Property & Equipment 172.03 167.81 Other Equity 393.39 368.46 Capital
Slide 11: Company Overview
Company Overview
Slide 12: Snapshot of Company
Snapshot of Company Strategic focus To become Leader in Hospital Business in India with 4 Strong Balance Sheet growing divisions contributing 38.25% to revenue in Total Debt to Equity at 0.21 FY24-25 in FY24-25 3 State of art manufacturing facilities in India – Rs. 1,353 Cr 1 Formulations and 2 APIs
Slide 13: Strong Business Model
Strong Business Model 01 Businesswise Revenue – Q4 FY25 Hospital Business API, Co. is major growth 03 Mkt & Hospital Others 43% driver 43% Trade 14% n 02 n Hospital Business API Business Critical Care Division API Legacy Business Intensive Care Division New Product pipeline Businesswise Reve
Slide 14: Vertically Integrated State of Art Manufacturing Capabilities
Vertically Integrated State of Art Manufacturing Capabilities Location Particulars Haridwar Hyderabad Vapi Artemis Biotech Themis Medicare Ltd. Themis Medicare Ltd. (Division of Themis Medicare Ltd.) Segment Formulations Synthetic APIs Synthetic APIs Tablets (Nos.) - 520 mn Ointment (No. of Tubes) -
Slide 15: Strong Research and Development Capabilities
Strong Research and Development Capabilities Continued Investment in R&D (Rs. Cr.) Business API Formulations 14.25 13.64 13.69 13.21 R&D 10 7 Analytical Lab 8.50 9 6 Development Product in a year with 5–8 20-24 documentation FY20-21 FY21-22 FY22-23 FY23-24 FY24-25 Products in work rolling 3–5 31 14
Slide 16: Way Ahead
Way Ahead
Slide 17: Hospital Business Opportunity
n Hospital Business Opportunity Why Hospital Business Segment? Growing market - Themis has strong foot in door through Critical Care Market Highly Fragmented unlike West where 3-4 players control 90% market share Opportunities to grow segments within HB High Entry Barriers Large Product Port
Slide 18: Our Aspirations
Our Aspirations Vision & Position Provide hospitals and health systems ‘The Best Experience Leader business model” to ensure customer satisfaction Leadership in Anesthesia and Critical Care Strategy Focus on Hospital business APIs to be developed - in-house New Target Markets consumption and
Slide 19: Thank You
Thank You It takes one word to change the world “POSSIBILITY” For further information, please contact: Mr. Pradeep Chandan Mr. Amit Sharma / Ms. Disha Shah Tel: +91 9867726686 / 9699060134 Themis Medicare Ltd Email: pradeep.chandan@themismedicare.com Adfactors PR Pvt Ltd Website: www.themismedicare.